Antihyperlipidemic Drugs: Statins (HMG-CoA Reductase Inhibitors)

STATINS (HMG-COA reductase inhibitor)

Mechanism of Action (MOA)

  • Statins act by inhibiting the enzyme HMG-CoA reductase, which controls the first committed step of cholesterol synthesis in the liver.

  • This inhibition effectively reduces the levels of cholesterol and low-density lipoprotein (LDL) in the bloodstream.

  • The action of statins at this rate-limiting step diminishes the production of mevalonate, a cholesterol precursor, leading to decreased cholesterol levels in the liver, prompting the liver to remove LDL from the blood to restore balanced cholesterol levels.

Potency and Examples

  • Statins are recognized as the most potent class of drugs for cholesterol and LDL lowering.

  • Examples include (RASLPF):

    • Rosuvastatin (Crestor)

    • Atorvastatin (Lipitor)

    • Simvastatin (Zocor)

    • Lovastatin (Mevacor)

    • Pravastatin (Pravachol)

    • Fluvastatin (Lescol)

  • Each of these statins has varying potencies, dosages, and pharmacokinetic profiles, allowing for individualized patient treatment plans.

Pharmacokinetics

  • Statins are primarily administered in the evening, correlating with the peak time of hepatic cholesterol production occurring overnight.

  • Atorvastatin (14 hours) and Rosuvastatin (19 hours) can be taken any time of the day due to their longer half-lives.

  • Food interactions: Most statins should be taken with food to enhance their bioavailability, except for Pravastatin, where food actually decreases its absorption; hence, it must be taken on an empty stomach.

  • Prodrugs: Lovastatin and Simvastatin (SL) are prodrugs that require metabolic activation, whereas Atorvastatin, Fluvastatin, and Rosuvastatin (RAF) are already active forms, with Rosuvastatin containing fluorine to increase its efficacy.

Adverse Effects

  • Hepatotoxicity: Regular monitoring of liver enzymes, ALT (Alanine Aminotransferase) and AST (Aspartate Aminotransferase) is crucial as they serve as biomarkers for liver toxicity associated with statin use.

  • Myositis & Rhabdomyolysis:

    • Myositis: Characterized by inflammation of muscle tissue, causing pain and weakness.

    • Rhabdomyolysis: A severe condition leading to the breakdown of muscle tissue and the release of muscle fiber contents into the bloodstream.

      • This can result in kidney damage if the released products are filtered by damaged kidneys.

  • Gastrointestinal Symptoms: Common issues include dyspepsia (indigestion), constipation, and abdominal pain.

  • Teratogenic Effects: Statins are contraindicated for use in pregnant women due to potential teratogenic risks; they may lead to birth defects if taken during pregnancy.

Treatment for Rhabdomyolysis

Research by Olivier Boutaud and Kevin Moore suggests that Acetaminophen (APAP) can be beneficial for treating Rhabdomyolysis by inhibiting hemoprotein-catalyzed lipid peroxidation, thereby attenuating the kidney damage that can occur in this condition.

Drug Interactions

  • Gemfibrozil (a fibrate): Increases the risk of rhabdomyolysis when combined with statins.

  • Warfarin: Lovastatin and Rosuvastatin can prolong bleeding time when used concurrently with this anticoagulant.

  • CYP450 3A4 inhibitors (CECNK) (such as cyclosporine, erythromycin, calcium channel blockers, niacin, or ketoconazole): Can increase the muscle toxicity of statins.

Contraindications

  • Statins must be avoided in patients with active liver disease, as it can exacerbate liver issues.

  • Not recommended for pregnant women or those planning to conceive due to teratogenic risks.

  • Contraindicated for lactating mothers due to potential risks to the nursing infant.